Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated With Cetuximab

Drugs in R and D - United Kingdom
doi 10.2165/11598190-000000000-00000
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

P2.01-35 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients With Advanced Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer
Cancer ResearchOncology
2009English

Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib

Oncotarget
Oncology
2017English

Correction: Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib

Oncotarget
Oncology
2019English

Analysis of the Incidence of Cetuximab-Induced Hypomagnesemia in Patients With Oral Cancer

Japanese Journal of Oral and Maxillofacial Surgery
2018English

Timing of Chemotherapy-Induced Neutropenia: The Prognostic Factor in Advanced Pancreatic Cancer Patients Treated With Gemcitabine / Gemcitabine-Based Chemotherapy

Oncotarget
Oncology
2017English

Incidence and Relative Risk of Peripheral Neuropathy in Cancer Patients Treated With Eribulin: A Meta-Analysis

Oncotarget
Oncology
2017English

Correction To: Neutropenia Management With Palbociclib in Japanese Patients With Advanced Breast Cancer

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2019English

The Risk and Predictors for Severe Radiation Pneumonitis in Lung Cancer Patients Treated With Thoracic Reirradiation

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy